DAXOR
THE BLOOD VOLUME COMPANY™

September 2026

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis," the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. Building on 50 years of experience and innovation, Daxor's patented, **newly FDA-cleared Blood Volume Analyzer (BVA) next generation device offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system**. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility. This vertically integrated infrastructure can produce 400+ BVA analyzers and 200,000 test kits annually, positioning the company for accelerated market expansion.

STOCK SYMBOL	DXR (Nasdaq)
Stock Price	$10.46 (a/o 09/08/2026)
Market Cap	$61.8M (a/o 09/08/26)
52-Wk Range	$8.56 - $14.26
Shares Outstanding	5.91M
Free Float	3.0M
Insider Ownership	49.5%

IMPROVED OUTCOMES

Significantly Reduce Heart Failure Mortality & Readmissions*

Propensity matched-control trial in community hospital | n = 245, Mixed HFpEF/HFrEF

- 82% 30-Day Mortality Rate (P<0.001)
- 56% 30-Day Readmission Rate (P<0.001)
- 86% 1-Year Mortality Rate (P<0.001)

Blood Volume Measurements Improved ICU Survival†

Prospective randomized control trial in surgical ICU | n = 100, 70% Septic Shock/Sepsis/40% ARDS

- 66% Mortality (P=0.03)
- 20% LOS (P=0.14)
- 36 Hour Earlier Treatment Decision
- 44% Change in Treatment Strategy Versus Standard Care

*JACC-HF, 2018;11:940-948 † Shock, 35 (2011), pp. 220-228.

BVA On Admission Results in 2.6 Days Reduction in Length of Stay

Analysis of 71 Hospitalized Heat Failure Patients. Strobeck JE, et al., *JACC-HF*, 2018;11:940-948. Presented at HFSA ASM 2022.

"BVA is a game-changer for fluid management. BVA provides precise, objective data, empowering value-based care through better outcomes and fewer hospitalizations."

– John L. Jefferies, MD, MBA, MPH
CMO, Daxor

HIGHLIGHTS

- ✓ **Next generation Daxor BVA™ FDA 510(k)-cleared in August 2025**
- ✓ Actionable results within 30 minutes
- ✓ "Gold Standard" methodology with 98% accuracy
- ✓ Over 80,000+ tests shipped to evaluate blood volume
- ✓ Over 180+ published peer reviewed studies, abstracts, presentations and trials
- ✓ Enables optimal patient outcomes shown to be highly cost effective
- ✓ Reimbursed with CPT & APC codes outpatient & inpatient settings
- ✓ Clean capital structure, strong balance sheet, no warrants, small float
- ✓ Broad and growing IP portfolio with patented technology
- ✓ Awarded patent for continuous remote monitoring
- ✓ Over $12+B in total addressable global market
- ✓ Grants awarded from NIH/CAPCaT, U.S. DoD
- ✓ Completed contract with the DoD for next generation technology
- ✓ ISO 13485 certified
- ✓ Vertical integration of Volumex® and Megatope® from supplier along with Glofil® to enhance existing suite of diagnostics
- ✓ Applied to report earnings with 1934 Act in 2026
- ✓ Raised $9M in January 2026 secondary offering

SALES MODEL

BVA Usage Agreement

Volumex® Single Use Kit Price

Daxor ezBVA℠ Lab Service

Razor/Razorblade Model

- Sale of BVA diagnostic systems
- Recurring sales of single use test kits
- Multi-million-dollar contract awards & grants

COMMERCIALIZATION CHANNELS

Industry Partners

Partnerships with MedAxiom, an ACC Company

Direct Sales Force

Major Medical Centers, Hospitals, Clinics, Government, & DoD

International Expansion Through Distributors With ISO 13485 Certification

CONTRACT & GRANT AWARDS

Over $7M Government Contract Awards For Next-Generation BVA Systems

- Next-generation Daxor BVA FDA 510(k) –cleared for combat and civilian use
- Novel patent-pending fluorescent tracer development
- BVA integration with Electronic Health Records

Grants and Matching Funds From Health & Human Services (NIH) Driving Clinical Validation & Technology Development

NHLBI and NIGMS grants to develop & validate clinical decision support tools for fluid management in heart failure & sepsis

GROWTH CATALYSTS & VALUE DRIVERS

Extensive R&D drives unique & expanding technology patent portfolio & product development.

Increasing partnership programs with leading clinical & commercial alliances.

Additional clinical outcomes supplementing the clinical & economic benefits of BVA.

New BVA is accurate, faster and easier to use, broadening its market.

EXCELLENT VALUE IN HEALTHCARE WITH REIMBURSEMENT

Blood Volume-Guided Treatment Extremely Cost-Effective‡

Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF

2.32 QALY
Average Life-Extension Per Patient

Well above 0.227 previously reported§

5X More Cost-Effective

Far below the threshold of $50,000



‡ Strobeck JE, Feldschuh J, Williams BA, et al. Cost-Effectiveness Analysis of Early Blood Volume-Guided Management in Hospitalized Heart Failure. Presented at HFSA 2020 Virtual Conference.
§J Rankin, et al. Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost–utility analyses. Heart Failure Reviews (2019), 24:549–563.

Over 75,000+ Tests Shipped to Leading Institutions

Geisinger · Allina Health · NYU Langone Medical Center · Prisma Health · NewYork-Presbyterian The University Hospital of Columbia and Cornell · Aspirus · Yale-New Haven Hospital · Westchester Medical Center · Mayo Clinic · Main Line Health Well ahead · DukeHealth

Daxor Corporation
107 Meco Lane, Oak Ridge, TN 37830
865-425-0555 | info@daxor.com | daxor.com

Forward Looking Statement: Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation does not constitute an offer to sell or a solicitation of an offer to buy any security.